-
This Biotech Name Could Be Best In Breed For 2017
Tuesday, June 13, 2017 - 8:46am | 879Read More...The biotech sector has seen better times this year after the disappointing showing in 2016. Calithera Biosciences Inc (NASDAQ: CALA) has been a stand-out performer in the sector, clocking gains in excess of 300 percent in the year-to-date period. But, does it qualify for the tag "best-in-...
-
Cowen & Co Reviews Expedia Earnings
Friday, May 1, 2015 - 8:37am | 233Read More...In a report published Friday, analysts at Cowen and Co. maintained their Outperform rating on Expedia Inc (NASDAQ: EXPE), as well as the price target of $115. The company reported its Q1 results with accelerating growth in its hotel business. Although losses at eLong (China) continued during the...
-
THRX Planning Rapid Response To FDA Requests On Vibativ NP SNDA
Monday, November 30, 2009 - 11:02am | 163Read More...Cowen and Co. maintains their “Neutral” rating for Theravance, Inc. (NASDAQ: THRX) after Theravance received a "complete response" letter from the FDA for the sNDA seeking the nosocomial pneumonia (NP) indication for Vibativ (telavancin). The Firm Said “Although the Vibativ NP pivotal trials (...
